Latest News and Press Releases

Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of December 31, 2022 was approximately $7.4 millionBalance sheet strengthened...

ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...

ROCKVILLE, Md., Jan. 11, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...

ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...

ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...

Study has enrolled over 1,800 patient samples at 4 U.S. clinical trial sitesPrimary endpoint for Unyvero UTI for urinary tract infection shows overall weighted average sensitivity of 96.4% and overall...

Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with...

Preliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and as of October 3, 2022 was approximately $13.3 millionAdditional...

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter...

Unyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100Focus on the detection of pneumonia patients infected with Acinetobacter baumannii ROCKVILLE, Md. and BASEL,...